Company

Companies of New York

Nuvation Bio

Nuvation Bio

Healthcare

Connections 1

Subscribe To favorites

Description

Nuvation Bio is a clinical-stage biopharmaceutical company. The Company is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer.

The Company is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor.

It is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.

Website

https://www.nuvationbio.com

Rating GlobalNY.biz

Mentions in the news View all

Quotes

All

NASA Names Astronaut Christina Koch Acting Deputy Chief Engineer

ISAACMAN Jared
ISAACMAN Jared

Christina has seen NASA engineering from both sides of the equation: developing complex systems on the ground and trusting them with her life in space

Blondie Reopens Its New York Story With High Noon

HARRY Deborah
HARRY Deborah

This music feels grounded in the present, shaped by who we are and how we’re living now

Pedro Pascal Discovers His Most Intimidating Co-Star Is a Cello

PASCAL Pedro
PASCAL Pedro

I’d never been so afraid

Paul Bettany Reveals the Call That Rebuilt His Hollywood Career

BETTANY Paul
BETTANY Paul

Maybe my career is over

Matthew Lillard Says Cult Fame Still Has Not Won Hollywood’s Trust

LILLARD Matthew
LILLARD Matthew

Nobody ever equates me with greatness